dorsaVi (ASX:DVL) - CEO, Dr Andrew Ronchi
CEO, Dr Andrew Ronchi
Source: North Road Physiotherapy
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • dorsaVi’s (DVL) share price has skyrocketed 900 per cent after becoming a strategic partner of QBE Australia.
  • Under the new commercial collab, DVL will provide QBE customers with wearable devices to help reduce injury claims
  • dorsaVi’s on-body sensors will be used in real-time, monitoring and measuring movements, muscle activity and movement risks
  • As a result, Australia’s second-largest global insurer has pre-allocated $250,000 over an initial 12 month period to provide its customer with access to dorsaVi’s technology
  • Company shares are still up a considerable 462 per cent on the market today, trading for 7.3 cents each

dorsaVi’s (DVL) share price has skyrocketed 900 per cent after becoming a strategic partner of QBE Australia.

Under the new commercial collab, DVL will provide QBE customers with wearable devices to help reduce injury claims.

As a result, Australia’s second-largest global insurer has pre-allocated $250,000 over an initial 12 month period to provide its customer with access to dorsaVi’s technology.

QBE Australia’s General Manager for People Risk, Rob Kosova, said over the past two years, the company has been looking at ways to reduce the risk of injury at work.

“New technologies offer great promise for taking a proactive role in making workplaces safer and we’re excited to be working with dorsaVi’s technology to achieve this,” he said.

“The consequences of workplace injuries can be significant and sometimes, sadly, long-lasting. SafeWork Australia puts the total cost of workplace injury and disease at around four per cent of gross domestic product (GDP) over one-third of these are due to body stressing or manual handling,” he added.

Via the wearable tech, dorsaVi’s on-body sensors will be used in real-time and will monitor and measure movements, muscle activity and movement risk.

dorsaVi CEO Dr Andrew Ronchi is excited to partner with QBE.

“One of the goals for insurers is to be able to pro-actively manage risk and have remote visibility on where their potential risks are, allowing insurers and corporate groups to mitigate these risks and prove solutions before they are implemented,” he said.

“We look forward to adding value to the QBE Australia business and to their clients’ businesses,” he added.

Company shares are still up a considerable 462 per cent on the market today, trading for 7.3 cents each at 12:57 pm AEST.

DVL by the numbers
More From The Market Online

Recce breathes better on positive lung infection drug pilot test results

Recce Pharmaceuticals Ltd has revealed positive results from its pilot test on synthetic drug Recce 327,…

What it takes to get a new drug to market in Australia

In this latest version of Thematica from TMO, we're taking a break from mines and battery…

4DMedical partners with West Los Angeles VA Medical Center for Veteran lung imaging study

Respiratory imaging technology company, 4DMedical (ASX:4DX) has entered into a research agreement with the West Los…

Recce Pharma picks up Chinese patent for anti-infective drugs

Recce Pharmaceuticals (ASX:RCE) has confirmed its receipt of a patent in China to protect its class…